大约70%的晚期乳腺癌为激素受体阳性HER2阴性，主要依靠内分泌治疗和化疗。对于内分泌治疗耐药患者，虽然细胞周期蛋白依赖性激酶CDK4/6抑制剂有效，但是仍然可能发生耐药。乳腺癌命运第四交响曲（DESTINY-Breast04）研究已经证实，德曲妥珠 ...

Following its initial approval at 150 mg, trastuzumab-strf has also been approved at 420 mg for the treatment of several HER2 ...

Celltrion announced that its Brazilian subsidiary won the Federal Government of Brazil’s bid to supply HERZUMA (trastuzumab-pkrb) for the fifth consecutive year, with around 660,000 vials to be ...

About Ignite Proteomics Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc., specializes in advanced RPPA technology for cancer diagnostics. As the only provider of a CLIA-accredited RPPA assay ...

The US Food and Drug Administration (FDA) has approved a 420 mg dosage strength of Hercessi (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab). Hercessi, a HER2/neu receptor antagonist, is ...

Accord BioPharma, the speciality division of Intas Pharmaceuticals, has received US Food and Drug Administration (FDA) ...

ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.

In a 10-year analysis of the ShortHER trial, high tumor-infiltrating lymphocytes were associated with improved survival in ...

Researchers explored HER2 testing discordance, biomarkers of response, patient-reported outcomes, and the risk of lung-related disease.

In this article, we discuss the global issue of drug shortages. We summarise our research where we developed a framework for ...

Drug shortages are becoming increasingly common. Shortages have been observed across a range of therapeutic areas, ...

Enhertu also improved the time to deterioration for pain and other factors in patients with HR-positive, HER2-low and ...